MedicalDevice Licensing.com
Pharmalicensing.com
Latest: Watch here for details of new products and services.
RSS Feeds
Advanced search

Login  Register

About Us
Pharmalicensing - Partnering solutions for the life sciences
 
Our Products
Overview
Partnering Search
Company Profiling
Deal Negotiation
PL Intelligence
Reports
Comparison
 
PL Intelligence
Overview
Industry news
Deals review
Press releases
Articles
 
Case Studies
See what others think about our service
 
Newsletter
Partnering update
Key reports
Subscribe
 
Quick Links
Profile now
Register now
Profiled companies
Featured events
Industry news
PR Newswire
Jobs
 
Contact Pharmalicensing
Send an email
Call us: +44 1904 520460
Request a callback
 
RSS Feeds
Keep up to date

Pharmalicensing
is a division of
UTEK Europe Ltd
UTEK Corporation
PR Newswire

Hospitals Must Take up Challenge to Tackle Clots

- Charity Welcomes Publication of Department of Health Tool

— LONDON, September 19

LONDON, September 19 /PRNewswire/ -- A new tool to help hospital doctors screen for Britain's most dangerous hospital killer is being rolled out across the country today and has the potential to save many of the 25,000 lives lost to the condition, but only if the measures are taken up by hospital managers, say Lifeblood: The Thrombosis Charity.

Hospital-acquired Deep Vein Thrombosis (DVT) is the commonest cause of hospital mortality, killing many more people in the UK than hospital -acquired infection. Yet, it is preventable with simple and effective risk assessment.

Lifeblood welcomed the Department of Health's DVT Risk Assessment tool, published today for hospitals, which comes eighteen months after the Chief Medical Officer, Sir Liam Donaldson recommended that all hospital patients should receive a risk assessment for DVT.

The charity called for the Department of Health to mandate DVT Risk Assessment, a measure which it says could save many of patients whose deaths are caused by a DVT contracted during their hospital stay.

Lifeblood has been campaigning for improved healthcare to prevent hospital acquired DVT. However, a report by a group of MPs last year revealed that your chance of being risk assessed for DVT was a postcode lottery; only one-third of Trusts were risk assessing all patients on admission.

Professor Beverley Hunt, Medical Director of Lifeblood said:

"Lifeblood congratulates the Department of Health for the excellent work it has put into developing this DVT risk assessment tool. This is great news for all patients and has the potential to prevent thousands of deaths due to hospital-acquired DVT.

"Many patients are unaware that their greatest risk going into hospital is developing a DVT. It is vital that all patients are risk assessed as DVT is often clinically silent and the patient may confuse their symptoms with less serious conditions.

"The publication of this national tool means that there should now be no excuses for hospitals not to risk assess patients. However, this cannot be allowed to sit gathering dust on the shelf while lives are lost to this neglected killer.

"Lifeblood hopes that the Department of Health will now mandate DVT risk assessment for all hospital patients, as it has done with the deep cleaning of hospitals, and urges the NHS to introduce it into clinical practice."

Notes to editors:

What is a DVT?

A deep vein thrombosis (DVT) is a clot which forms in a deep vein, usually in the leg. Deep veins are the larger veins that go through the muscles and transport blood to and from the heart. When a blood clot occurs, it forms a plug that can interrupt this flow.

Is DVT Serious?

DVT can be a very serious and potentially life-threatening condition. If the clot breaks off, it can travel in the blood stream, through the heart and become lodged in the lung. This is known as a pulmonary embolism (PE). It can happen hours or even days after a DVT. In severe cases it can be fatal.

Hospital acquired DVT - DVT causes 10% of all hospital deaths. (Health Select Committee Inquiry into Venous thomboembolism in hospitalised patients, March 2005) - 52% of patients are at risk from DVT. (Cohen AT et al. A large-scale, global observational study of venous thromboembolism risk and prophylaxis in the acute hospital care setting: the ENDORSE study. Abstract Ndegrees 1827, presented at the XXIst Congress of the International Society on Thrombosis and Haemostasis, Geneva, 8 July 2007) - DVT has a 30% morbidity rate but the figure drops to between 2-8% if the patient is treated with the appropriate therapy. (Task Force Report: Guidelines on diagnosis and management of acute pulmonary embolism. Torbicki, EJR, et al. Eur Heart Journal 2000; 21, 1301-1336.) Based on 2005 figures for MRSA and Clostridium difficile

Website: http://www.thrombosis-charity.org.uk

Related news

Clients in focus...

Get the Flash Player to see this rotator.

Partnering and licensing intelligence in life sciences industry
Press releases: Pharmalicensing current industry press releases.

© Copyright 1995-2009 Pharmalicensing, a division of UTEK Europe Ltd UTEK Corporation All rights reserved. Terms and Conditions | Contact us